Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 14/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756384 | 0.85 | FFAR4 (0.49) | FFAR4MTNR1B | |
| SCHEMBL8372012 | 0.84 | ALDH1A1 (0.44) | FFAR4ALDH1A1POLBMTNR1BKMT2A | |
| SCHEMBL4680033 | 0.84 | MRGPRX4 (0.40) | ALDH1A1MTNR1BKMT2A | |
| SCHEMBL5746010 | 0.81 | HSD17B10 (0.47) | FFAR4ALDH1A1POLBMTNR1BKMT2A | |
| SCHEMBL697670 | 0.79 | CHRM2 (0.50) | ALDH1A1MTNR1B | |
| SCHEMBL25254051 | 0.79 | CA2 (0.46) | FFAR4ALDH1A1MTNR1B | |
| SCHEMBL14811791 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TRPV3POLBKMT2A | |
| SCHEMBL27634255 | 0.78 | MTNR1B (0.39) | FFAR4ALDH1A1TRPV3POLBMTNR1B | |
| SCHEMBL16950678 | 0.78 | NQO1 (0.48) | FFAR4ALDH1A1KMT2A | |
| SCHEMBL15604689 | 0.77 | MTNR1B (0.36) | FFAR4MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660184-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING HYDROXAMATES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024159287-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING HYDROXAMATES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| EP-1371657-A1 | Transition-metal complexes and use thereof in transition-metal catalysed reactions.. | Bayer Aktiengesellschaft (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030220512-A1 | Novel transition metal complexes and their use in transition metal-catalysed reactions | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220512-A1 | Novel transition metal complexes and their use in transition metal-catalysed reactions | AP1M1, AP3M1, CYC1 | FFAR4 4866/4885ALDH1A1 1042/4885TRPV3 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.